<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>RGE-GCN: Recursive Gene Elimination with Graph Convolutional Networks for RNA-seq based Early Cancer Detection - Health AI Hub</title>
    <meta name="description" content="RGE-GCN is a novel framework that integrates Graph Convolutional Networks with recursive gene elimination for RNA-seq based early cancer detection and biomarker">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>RGE-GCN: Recursive Gene Elimination with Graph Convolutional Networks for RNA-seq based Early Cancer Detection</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2512.04333v1" target="_blank">2512.04333v1</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-12-03
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Shreyas Shende, Varsha Narayanan, Vishal Fenn, Yiran Huang, Dincer Goksuluk, Gaurav Choudhary, Melih Agraz, Mengjia Xu
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.LG, cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 1.00 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2512.04333v1" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2512.04333v1" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">RGE-GCN is a novel framework that integrates Graph Convolutional Networks with recursive gene elimination for RNA-seq based early cancer detection and biomarker discovery. It addresses the challenge of high-dimensional gene expression data by identifying reliable, compact, and interpretable sets of biomarkers. The method consistently outperforms traditional differential expression tools in accuracy and F1-scores across various cancer types, with identified genes aligning to known cancer pathways.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is crucial for improving cancer survival rates by enabling earlier, more accurate, and mechanistically interpretable detection through novel biomarker discovery from RNA-seq data, which can guide precision medicine and targeted therapies.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The AI application involves using Graph Convolutional Networks (GCNs) within the RGE-GCN framework to analyze high-dimensional RNA-seq gene expression data. The AI system classifies cancer versus normal samples, identifies the most informative genes (biomarkers), and recursively refines this set for early cancer detection. This provides an AI-driven tool for genomic analysis in cancer diagnosis and biomarker development.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses the challenge of identifying reliable biomarkers from high-dimensional RNA-seq data for early cancer detection, overcoming limitations of conventional statistical methods.</li>
                    
                    <li>Introduces RGE-GCN, a unified pipeline combining feature selection and classification using Graph Convolutional Networks (GCNs) and Integrated Gradients.</li>
                    
                    <li>Employs a recursive gene elimination strategy that iteratively removes less relevant genes, converging on a compact, predictive, and interpretable set of biomarkers.</li>
                    
                    <li>Achieved consistently higher accuracy and F1-scores on synthetic data and real-world RNA-seq cohorts (lung, kidney, cervical cancers) compared to standard tools like DESeq2, edgeR, and limma-voom.</li>
                    
                    <li>The selected gene biomarkers demonstrated strong biological relevance, aligning with well-known cancer pathways including PI3K-AKT, MAPK, SUMOylation, and immune regulation.</li>
                    
                    <li>Shows promise as a generalizable approach for early cancer detection and biomarker discovery across different cancer types, enhancing its potential for broad applicability.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>RGE-GCN constructs a graph from gene expression profiles, where nodes represent genes. A Graph Convolutional Network (GCN) is then employed to classify cancer versus normal samples. Integrated Gradients, an explainable AI technique, is utilized to identify and rank the most informative genes contributing to the classification decision. By recursively eliminating less relevant genes based on their importance scores, the model converges on a compact, optimized set of biomarkers.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>RGE-GCN consistently outperformed standard differential expression analysis tools (DESeq2, edgeR, limma-voom) by achieving higher accuracy and F1-scores across synthetic and real RNA-seq datasets from lung, kidney, and cervical cancers. Importantly, the identified gene biomarkers were significantly enriched in established cancer-related pathways such as PI3K-AKT, MAPK, SUMOylation, and immune regulation, providing strong biological validation for their clinical relevance.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>This framework has the potential to significantly enhance clinical practice by offering a more robust and accurate method for early cancer detection. The discovery of interpretable, pathway-aligned biomarkers could lead to the development of new diagnostic panels, improved patient stratification, and the identification of novel therapeutic targets, ultimately facilitating more personalized and effective cancer management and improving patient outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state any specific limitations of the RGE-GCN method. Further details on data size constraints, computational cost, or potential biases would typically be discussed in the full paper.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>While not explicitly detailed, the assertion of RGE-GCN as a 'generalizable approach' implies future research could focus on its application to a broader spectrum of cancer types, integration with other multi-omics data, or potential translation into clinical diagnostic workflows for prospective validation.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Lung Cancer</span>
                    
                    <span class="tag">Kidney Cancer</span>
                    
                    <span class="tag">Cervical Cancer</span>
                    
                    <span class="tag">Molecular Diagnostics</span>
                    
                    <span class="tag">Genomics</span>
                    
                    <span class="tag">Precision Medicine</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">RNA-seq</span>
                    
                    <span class="tag tag-keyword">Early Cancer Detection</span>
                    
                    <span class="tag tag-keyword">Biomarker Discovery</span>
                    
                    <span class="tag tag-keyword">Graph Convolutional Networks</span>
                    
                    <span class="tag tag-keyword">Machine Learning</span>
                    
                    <span class="tag tag-keyword">Feature Selection</span>
                    
                    <span class="tag tag-keyword">Oncology</span>
                    
                    <span class="tag tag-keyword">Gene Expression</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Early detection of cancer plays a key role in improving survival rates, but identifying reliable biomarkers from RNA-seq data is still a major challenge. The data are high-dimensional, and conventional statistical methods often fail to capture the complex relationships between genes. In this study, we introduce RGE-GCN (Recursive Gene Elimination with Graph Convolutional Networks), a framework that combines feature selection and classification in a single pipeline. Our approach builds a graph from gene expression profiles, uses a Graph Convolutional Network to classify cancer versus normal samples, and applies Integrated Gradients to highlight the most informative genes. By recursively removing less relevant genes, the model converges to a compact set of biomarkers that are both interpretable and predictive. We evaluated RGE-GCN on synthetic data as well as real-world RNA-seq cohorts of lung, kidney, and cervical cancers. Across all datasets, the method consistently achieved higher accuracy and F1-scores than standard tools such as DESeq2, edgeR, and limma-voom. Importantly, the selected genes aligned with well-known cancer pathways including PI3K-AKT, MAPK, SUMOylation, and immune regulation. These results suggest that RGE-GCN shows promise as a generalizable approach for RNA-seq based early cancer detection and biomarker discovery (https://rce-gcn.streamlit.app/ ).</p>
            </section>

            
            <section class="paper-section">
                <h2>Comments</h2>
                <p>12 pages, 2 figures</p>
            </section>
            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>